UPDATED OVERALL SURVIVAL ANALYSIS IN OCEANS, A RANDOMIZED PHASE 3 TRIAL OF GEMCITABINE (G) plus CARBOPLATIN (C) AND BEVACIZUMAB (BV) OR PLACEBO (PL) FOLLOWED BY BV OR PL IN PLATINUM-SENSITIVE RECURRENT EPITHELIAL OVARIAN (ROC), PRIMARY PERITONEAL (PPC), OR FALLOPIAN TUBE CANCER (FTC)

被引：0
|
作者：
Aghajanian, C. [1 ]
Nycum, L. R. [2 ]
Goff, B. [3 ]
Nguyen, H. [4 ]
Husain, A. [5 ]
Blank, S. V. [6 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Gynecol Med Oncol Serv, New York, NY 10021 USA
[2] Forsyth Reg Canc Ctr, Dept Obstet Gynecol, Winston Salem, NC USA
[3] Univ Washington, Sch Med, Dept Obstet Gynecol, Seattle, WA USA
[4] Genentech Inc, Biostat, San Francisco, CA 94080 USA
[5] Genentech Inc, Avastin Ovarian Canc Program, San Francisco, CA 94080 USA
[6] NYU Sch Med, Div Gynecol Oncol, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：319 / 319
页数：1
相关论文
共 19 条
  • [1] Results from a 2nd interim OS analysis in OCEANS: A randomized phase 3 trial of gemcitabine (G), carboplatin (C) and bevacizumab (BV) followed by BV to disease progression in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC)
    Aghajanian, C.
    Blank, S.
    Goff, B.
    Judson, P.
    Nycum, L.
    Sovak, M.
    Yi, J.
    Husain, A.
    GYNECOLOGIC ONCOLOGY, 2012, 125 (03) : 773 - 773
  • [2] An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer.
    Aghajanian, Carol
    Blank, Stephanie V.
    Goff, Barbara Ann
    Judson, Patricia Lynn
    Nycum, Lawrence R.
    Sovak, Mika A.
    Yi, Jing
    Husain, Amreen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Independent radiologic review of OCEANS, a phase III trial of carboplatin, gemcitabine, and bevacizumab or placebo for the treatment of platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Aghajanian, C.
    Makhija, S.
    Rutherford, T.
    Sharma, S.
    Nycum, L.
    Sovak, M.
    Nguyen, H.
    Yi, J.
    Husain, A.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S30 - S31
  • [4] A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC).
    Tew, William P.
    Sill, Michael
    McMeekin, D. Scott
    Secord, Angeles Alvarez
    Bonebrake, Albert J.
    Schilder, Jeanne
    Stuckey, Ashley
    Rice, Laurel
    Tewari, Krishnansu Sujata
    Aghajanian, Carol
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Efficacy in Patient Subgroups in OCEANS, a Randomized, Double-blinded, Placebo-controlled, Phase 3 Trial of Chemotherapy ± Bevacizumab in Patients with Platinum-sensitive Recurrent Epithelial Ovarian (OC), Primary Peritoneal (PPC), or Fallopian Tube Cancer (FTC)
    Aghajanian, C.
    Blank, S. V.
    Goff, B.
    Judson, P. L.
    Makhija, S.
    Sharma, S. K.
    Nycum, L. R.
    Yi, J.
    Husain, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 5 - 5
  • [6] OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)
    Aghajanian, C.
    Finkler, N. J.
    Rutherford, T.
    Smith, D. A.
    Yi, J.
    Parmar, H.
    Nycum, L. R.
    Sovak, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
  • [7] OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC).
    Aghajanian, C.
    Finkler, N. J.
    Rutherford, T.
    Smith, D. A.
    Yi, J.
    Parmar, H.
    Nycum, L. R.
    Sovak, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer
    del Carmen, Marcela G.
    Micha, John
    Small, Laurie
    Street, Daron G.
    Londhe, Anil
    McGowan, Tracy
    GYNECOLOGIC ONCOLOGY, 2012, 126 (03) : 369 - 374
  • [9] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Aghajanian, Carol
    Blank, Stephanie V.
    Goff, Barbara A.
    Judson, Patricia L.
    Teneriello, Michael G.
    Husain, Amreen
    Sovak, Mika A.
    Yi, Jing
    Nycum, Lawrence R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2039 - 2045
  • [10] Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
    Aghajanian, Carol
    Goff, Barbara
    Nycum, Lawrence R.
    Wang, Yan V.
    Husain, Amreen
    Blank, Stephanie V.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 10 - 16
12